Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunization regimen consisting of two separate vaccines administered during the same healthcare visit: - **Influenza vaccine** is an inactivated or live attenuated viral vaccine that stimulates the immune system to produce antibodies against influenza virus strains included in the formulation. It is used for the prevention of seasonal influenza. - **PCV13 (pneumococcal 13-valent conjugate vaccine)**, also known as Prevnar 13, is a conjugate bacterial vaccine containing polysaccharides from 13 serotypes of *Streptococcus pneumoniae* linked to a carrier protein (CRM197). It induces active immunity by stimulating antibody production against these pneumococcal serotypes, preventing invasive diseases such as pneumonia, meningitis, and bacteremia caused by these bacteria. These vaccines are often co-administered in clinical practice for comprehensive protection against both influenza viruses and pneumococcal disease—especially in older adults or those with certain risk factors. Each component works independently; they are not physically combined but given at different injection sites during the same visit[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine + PCV13.